Additionally, a study revealed significant positive correlations between CML and serum levels of sclerostin and fibroblast growth factor 23 (FGF23), both of which are secreted by osteocytes and known to impair bone mineralization [43]. This evidence concerns the gene FGF23 and chronic myelogenous leukemia, BCR-ABL1 positive.